ALA narrows focus to iNKT cell therapy

Our early stage biotech Investment Arovella Therapeutics (ASX:ALA) is now fully focussed on its iNKT cell therapy after deciding to discontinue its legacy OroMist based products.

The benefit of not pursuing any further work on OroMist products comes in the form of $1.5M annual cost savings.

We think it's a good strategic move for ALA to prioritise its core treatment.

The move will incur a one off $300k restructuring cost, but we know how hard it is for small-caps to raise funds and long-term, this makes sense.

A lower cash burn is always welcome.

ALA is also particularly clear about what’s in the pipeline in terms of news flow, and gave the following timetable for progressing their iNKT cell therapy:

What’s next for ALA? After partnering with ASX biotech giant Imugene to work on a treatment that could target 90% of all cancers (solid tumours), we’re particularly looking forward to the in vitro and in vivo study outcomes.